Please see clinicaltrials.gov entry describing the Ocrelizumab PPMS trial: <click here
This study is based on the postive results of the PPMS Rituximab trial that I have commented on before.
Please note that Ocrelizumab is the follow-on compound of Rituximab; both these drugs are monoclonal antibodies that target a protein CD20 that is expressed on B cells. Exactly how these drugs work is not known. However, I suspect that they may work by suppressing EBV infection with the body. The response of MS to anti-CD20 therapies is one of the arguments I use to support my EBV-MS causation theory.
"Our site is now recruiting for the ocrelizumab trial."